The global tissue plasminogen activator market is estimated to be valued at US$ 614.9 Mn in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period of 2024 to 2030.

Tissue plasminogen activator (tPA) is a protein involved in the breakdown of blood clots. It helps restore blood flow by dissolving clots and is primarily used for the treatment of ischemic stroke and myocardial infarction. The increasing incidence of cardiovascular diseases such as heart attacks and strokes globally is one of the major drivers of growth of this market.

Key Takeaways

Key players operating in the tissue plasminogen activator market include Siemens Healthineers AG, GE Healthcare, Koninklijke Philips N.V., Canon Medical Systems Corporation, Shimadzu Corporation, Hitachi, Ltd., Carestream Health, Inc., Medtronic plc, Stryker Corporation, Terumo Corporation, Boston Scientific Corporation, AngioDynamics, Inc., Penumbra, Inc., MicroPort Scientific Corporation, Cook Medical LLC. Siemens Healthineers AG dominates the market with its portfolio of tPA products, including Activase.

The Tissue Plasminogen Activator Market Trends is witnessing significant opportunities in the developing regions due to the increasing awareness regarding cardiovascular diseases, growth in healthcare infrastructure, and rising healthcare expenditure. Key players are expanding their presence in these regions through partnerships and acquisitions to gain a larger market share. For instance, in 2021, Penumbra acquired European medical device company MicroVention to strengthen its international footprint.

Get More Insights on- Tissue Plasminogen Activator Market